Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00122902
Other study ID # R01AT001147-01
Secondary ID
Status Completed
Phase N/A
First received July 19, 2005
Last updated August 17, 2006
Start date February 2002
Est. completion date February 2004

Study information

Verified date August 2006
Source National Center for Complementary and Integrative Health (NCCIH)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

This study is assessing the extent of spirituality in patients with HIV/AIDS and will determine the relationship between spirituality, health status, and the will to live.


Description:

Approximately 1,000,000 Americans have HIV/AIDS. Although advances in treatment have made HIV/AIDS a relatively manageable chronic disease, the disease can cause significant morbidity and mortality. Surprisingly, research has found that some HIV/AIDS patients feel that their life is better than it was before they had HIV/AIDS. Many of these patients show a strong will to live and often express a preference for longevity over quality of life. Patients who prefer longevity often ascribe their feeling to spiritual growth, or finding a meaning to life. This study is examining the spiritual beliefs of HIV/AIDS patients and will determine the relationship between spirituality, health status, and the will to live.

The study consists of interviews with HIV/AIDS patients from Cincinnati and Washington, D.C. who have been interviewed twice over 12 to 18 months. During the interviews, participants completed self-report scales to assess their quality of life, life satisfaction, concerns about medication, trust in their health care providers, depressive symptoms, self-esteem, optimism, and various clinical and demographic variables. Participants were also asked about their spiritual well-being; spiritual beliefs; spiritual, religious, and social support; and overall functioning.


Recruitment information / eligibility

Status Completed
Enrollment 350
Est. completion date February 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of HIV or AIDS

Exclusion Criteria:

Study Design

Time Perspective: Longitudinal


Related Conditions & MeSH terms


Locations

Country Name City State
United States Division of General Internal Medicine, University of Cincinnati Medical Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Jiang Y, Chen C, Pei L. [Mechanism of Se-Indocalamus tessdatus polycassine(S-ITPS) against human immunodeficiency virus type 1 (HIV-1)]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2000 Mar;14(1):56-9. — View Citation

Luckhaupt SE, Yi MS, Mueller CV, Mrus JM, Peterman AH, Puchalski CM, Tsevat J. Beliefs of primary care residents regarding spirituality and religion in clinical encounters with patients: a study at a midwestern U.S. teaching institution. Acad Med. 2005 Jun;80(6):560-70. — View Citation

Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care. 2006 Feb;44(2):158-66. — View Citation

Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making. 2003 Sep-Oct;23(5):414-21. — View Citation

Yi MS, Luckhaupt S, Mrus JM, Tsevat J. Do medical house officers value the health of veterans differently from the health of non-veterans? Health Qual Life Outcomes. 2004 Apr 7;2:19. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2